NCT05265962 2022-03-04Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeThe First Affiliated Hospital of Zhengzhou UniversityPhase 2 Unknown85 enrolled